Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PPOX | P50336 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16531967 | 0.93 | DGAT1 (0.51) | DGAT1TP53SMN1; SMN2LMNA | |
| SCHEMBL16531968 | 0.89 | TP53 (0.36) | DGAT1TP53P2RX3SMN1; SMN2LMNA | |
| SCHEMBL16532112 | 0.87 | DGAT1 (0.51) | DGAT1TP53SMN1; SMN2LMNA | |
| SCHEMBL17907369 | 0.87 | DGAT1 (0.51) | DGAT1TP53ALDH1A1 | |
| SCHEMBL17907290 | 0.86 | DGAT1 (0.50) | DGAT1TP53 | |
| SCHEMBL16532105 | 0.86 | DGAT1 (0.51) | DGAT1TP53 | |
| SCHEMBL16532013 | 0.86 | DGAT1 (0.49) | DGAT1TP53SCN9ASCN10A | |
| SCHEMBL17907288 | 0.84 | DGAT1 (0.47) | DGAT1TP53 | |
| SCHEMBL17907301 | 0.82 | DGAT1 (0.49) | DGAT1TP53 | |
| SCHEMBL16532005 | 0.81 | TP53 (0.37) | DGAT1TP53SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042907-B1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | QUINGDAO HUANGHAI PHARMACEUTICAL CO LTD (CN) | 2021-01-13 | — | — | EP | disclosed |
| EP-3042907-B1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | QUINGDAO HUANGHAI PHARMACEUTICAL CO LTD (CN) | 2021-01-13 | — | — | EP | disclosed |
| US-9809604-B2 | DGAT1 inhibitor and preparation method and use thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-9809604-B2 | DGAT1 inhibitor and preparation method and use thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-9809604-B2 | DGAT1 inhibitor and preparation method and use thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| EP-3042907-A1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Medshine Discovery Inc. (CN) | 2016-07-13 | — | — | EP | disclosed |
| EP-3042907-A1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Medshine Discovery Inc. (CN) | 2016-07-13 | — | — | EP | disclosed |
| WO-2015024486-A1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | 南京明德新药研发股份有限公司 (CN) | 2015-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | DGAT1, DGAT2, LCAT | DGAT1 1/4885TP53 4424/4885P2RX3 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.